MELA Sciences to Report Second Quarter 2014 Financial Results on Wednesday, August 13
Conference Call to Follow at 4:30 p.m. EDT
August 04, 2014 16:01 ET | Source: MELA Sciences
IRVINGTON, N.Y., Aug. 4, 2014 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind® system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, will release second quarter 2014 financial results on Wednesday, August 13, after the market close. MELA Sciences President and Chief Executive Officer, Rose Crane, and Chief Financial Officer, Robert Cook, will host a conference call at 4:30pm Eastern Time to review the Company's progress and answer questions.
Conference Call Details:
Date: Wednesday, August 13, 2014
Time: 4:30 p.m. Eastern Time
Toll Free: 800-274-0251
International: 719-325-2284
Passcode: 2866769
Webcast: http://melasciences.com/investors/home
Replays, Available through August 29:
Toll Free: 877-870-5176
International: 858-384-5517
Replay PIN: 2866769
About MELA Sciences, Inc. www.melasciences.com
MELA Sciences is a medical technology company dedicated to designing and developing innovative software-driven technology for the clinical early detection and prevention of skin cancer. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature.
Media
Diana Garcia Redruello
MELA Sciences, Inc.
212-518-4226
Investors
Andrew McDonald
LifeSci Advisors, LLC
646-597-6987
- See more at: http://globenewswire.com/news-release/2014/08/04/655834/10092822/en/MELA-Sciences-to-Report-Second-Quarter-2014-Financial-Results-on-Wednesday-August-13.html#sthash.LCb0Xh5S.dpuf
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM